Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772274 | 0.96 | MAPK14 (0.60) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6769842 | 0.93 | MAPK14 (0.56) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6773931 | 0.92 | MAPK14 (0.54) | MAPK14BRD4BRDT | |
| SCHEMBL6773952 | 0.92 | MAPK14 (0.56) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6774535 | 0.92 | MAPT (0.57) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6624696 | 0.91 | MAPK14 (0.57) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6775176 | 0.91 | MAPK14 (0.66) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6779673 | 0.90 | MAPK14 (0.62) | MAPK14BRD4BRDTCYP1A2 | |
| SCHEMBL6778965 | 0.90 | MAPK14 (0.53) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6779629 | 0.90 | MAPK14 (0.55) | MAPK14BRD4MAPTL3MBTL1BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-01-16 | — | — | US | claimed |
| US-6727364-B2 | ANTIINFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | IL4, IL1A, IL2 | MAPK14 3429/4885BRD4 389/4885MAPT 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.